MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study conducted at a single center to collect and review clinical, biological, and treatment information on patients with Philadelphia-negative myeloproliferative neoplasms. It includes both prefibrotic and overt primary myelofibrosis, secondary myelofibrosis, polycythemia vera, and essential thrombocythemia, aiming to build a database for better understanding of these diseases. The project retrospectively and prospectively aggregates data to examine outcomes and trends over time. Eligible participants are 16 years or older with these diagnoses and at least 6 months of follow-up. No interventional treatment is prescribed by the study protocol; data collection and analysis are the primary activities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients 16 years of age and older
* Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications)

Exclusion Criteria:

* Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis
* Follow up of less than 6 months

Where it's running

• Ospedale Maggiore Policlinico
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Barbara Mora, MD
• Email: barbara.mora@policlinico.mi.it
• Phone: +39 0255033345

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Pacritinib Effectiveness in Real-world Settings

  This real-world study will see how pacritinib works for adults with myelofibrosis by looking back at medical records from several centers.

  Recruiting at 5 sites Swedish Orphan Biovitrum · New Haven, Connecticut and 4 other locations · NCT07774455

• Test of bomedemstat for polycythemia vera in adults

  This study tests bomedemstat (MK-3543) to see if it helps people with polycythemia vera reach healthier blood counts compared with standard treatments.

  Recruiting at 5 sites Phase 2/3 Merck Sharp & Dohme LLC · Newark, Delaware and 4 other locations · NCT07722611

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• PRT12396 for people with high-risk polycythemia vera or myelofibrosis

  The team will try the oral drug PRT12396 in people with high-risk polycythemia vera or myelofibrosis to find safe doses and look for early signs of benefit.

  Recruiting at 22 sites Phase 1 Prelude Therapeutics Incorporated · Los Angeles, California and 21 other locations · NCT07469891

• Sapablursen added to standard care for people with polycythemia vera

  This trial will test whether adding sapablursen to standard therapy can reduce the need for phlebotomy in people with polycythemia vera who remain phlebotomy-dependent.

  Recruiting at 38 sites Phase 3 Ono Pharmaceutical Co., Ltd. · Orange, California and 37 other locations · NCT07429266

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.